Zimbabwe has rejected a major American health deal valued at $367m (£272m) spanning five years over Washington's demand for confidential information.
This rejection came to light after a internal memorandum dated December was disclosed, which showed Head of State Emmerson Mnangagwa deemed the deal was "lopsided".
A government spokesman has since explained that the United States was demanding access to health data for scientific study and commercial purposes but refused to guarantee the resulting advantages from any future vaccines.
"We must now begin the challenging and unfortunate process of ending our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had provided more than $1.9bn in health funding to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged more dialogue to secure a deal acceptable to both sides so the nation's critical HIV treatment initiative can proceed.
Broader Context
This rejection comes after a comparable case in neighbouring Kenya, where a high court halted a similar health funding agreement after legal challenges were filed about the safety of citizens' medical information.
Since returning to office recently, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
USAID had managed assistance for the US government, but Trump argued its spending was "wasteful" and his government was seeking direct bilateral deals to enhance openness and accountability.
According to statements, 16 African countries have so far signed these new health pacts, representing over $18.3bn of fresh investment.
Details of the Rejected Deal
The money for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation could have provided significant benefits for the people of Zimbabwe, especially the 1.2 million men, women and children currently on HIV treatment through US-supported initiatives," Tremont commented.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"The proposal required Zimbabwe to share its genetic material and health information for a long time, with no corresponding assurance of benefiting from any scientific breakthroughs – such as new medicines or tests – that could result from that provided information," he stated.
"Put simply, our country would provide the raw materials for medical research without any certainty that the final treatments would be available to our population should a new pandemic emerge."
National Interest and International Frameworks
Mangwana further said that the American exit from the global health body and its push of bilateral health agreements were disrupting systems already set up via the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing system designed to deal with future global health emergencies.
"This system is intended to guarantee that when a country provides its data, the resulting advantages – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the capability to develop them."
These objections over the US deal "are not meant as opposition to America," he added.
"We encourage ongoing discussions with our American counterparts on how future co-operation might be designed in a manner that respects the independence and interests of each country."
Medical Community Response
Medical experts stated it recognised the government's concerns, but suggested that talks need to persist since a large portion of the country's HIV programmes relied on international support.
"Where specific concerns exist, including those relating to information security or agreement terms, these can frequently be resolved via detailed discussion and mutually agreed protections," it added.
This impasse highlights the continuing debate between receiving much-needed international aid and safeguarding local interests in an increasingly data-driven world.